Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Dermatology | Oncology | Family Medicine
Search Medical Condition
Melanoma Clinical Trials
A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (541) clinical trials
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
To compare overall survival (OS) of patients with resected Stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b or ipilimumab versus MK-3475 (pembrolizumab)
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part B)
You are being asked to take part in this research study because you were diagnosed with a type of cancer called melanoma. Although your melanoma has been removed by surgery, you are at risk for having the melanoma come back (recur). People who are at risk for melanoma recurrence are ...
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)
This randomized phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances ...
CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01274338?term=E1609&rank=1
A Washington University research study seeks participants with ocular melanoma.
The main purpose of the study is to look at the safety and efficacy of a treatment for ocular melanoma. The study will last about 3 years (1 year of treatment and 2 years of follow up by phone). Participation includes screening procedures including medical history, endoscopy, CT scans, MRI ...
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in subjects with advanced or metastatic malignancies.
A Washington University research study seeks participants with cancer.
The purpose of the study is to develop new tests to predict the outcome of immunotherapy. There are up to 2 study visits. There may be the opportunity to participate in additional visits in the future. Each visit will last 30 to 50 minutes. There will be urine collection, survey, ...
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
The ILLUMINATE-301 study will look at the safety and effectiveness of an investigational drug called tilsotolimod (IMO-2125) in combination with an already approved treatment, an immunotherapy drug called Yervoy® , also known as ipilimumab. This combination will be compared to Yervoy® given by itself in patients who have refractory melanoma, ...
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose ...
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with ...
